Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Opal Therapeutics Raises $1.25M To Scale 'Uterus in a Dish' Drug Discovery

8 August 2026 · By · Wire by Fusion42

Published

8 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at femtechinsider.com →

◆ Verified

Fusion42 · 28 August 2026 · Fusion42 review

Opal Therapeutics secured a $1.25 million NSF SBIR Phase II award to scale its patient-derived 'uterus in a dish' drug discovery platform, improving preclinical modelling for women's health conditions like endometriosis and fibroids.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now access more human-relevant uterine tissue models to speed drug testing and cut failure rates. If you develop or partner in women's health drugs, these models open a clearer path to clinic-ready candidates.

◆ Coverage

1 source · 8 Aug 2026

◆ Related on Wire

◆ Topics

Biotechwomen's-healthpreclinical-modelsorganoidsdrug-discoveryfemtech